Given these facts, we used SVM which integrated APOE genotype, CSF biomarkers (Aβ, Tau, and pTau), and neuroimaging biomarkers (insula volumes and altered regional IFC strengths) to classify AD spectrum population who are difficult to assess or stage diagnosis. The gene discussed is MAPT; the disease is Alzheimer disease.